Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.
Identifieur interne : 007A47 ( Main/Exploration ); précédent : 007A46; suivant : 007A48Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.
Auteurs : B V Babu [Inde] ; K. Rath ; A S Kerketta ; B K Swain ; S. Mishra ; S K KarSource :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ] ; 2006.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (effets indésirables), Albendazole (usage thérapeutique), Animaux, Association de médicaments, Calendrier d'administration des médicaments, Contrôle des maladies contagieuses (), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Femelle, Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Humains, Incidence, Inde, Maladies endémiques (), Mâle, Observance thérapeutique, Résultat thérapeutique, Études de suivi, Évaluation de programme.
- MESH :
- effets indésirables : Albendazole, Diéthylcarbamazine, Filaricides.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Diéthylcarbamazine, Filaricides.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Association de médicaments, Calendrier d'administration des médicaments, Contrôle des maladies contagieuses, Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique, Humains, Incidence, Inde, Maladies endémiques, Mâle, Observance thérapeutique, Résultat thérapeutique, Études de suivi, Évaluation de programme.
- Wicri :
- geographic : Inde.
English descriptors
- KwdEn :
- Adolescent, Adult, Albendazole (adverse effects), Albendazole (therapeutic use), Animals, Child, Child, Preschool, Communicable Disease Control (methods), Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Drug Administration Schedule, Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (prevention & control), Endemic Diseases (prevention & control), Female, Filaricides (adverse effects), Filaricides (therapeutic use), Follow-Up Studies, Humans, Incidence, India, Male, Middle Aged, Patient Compliance, Program Evaluation, Treatment Outcome.
- MESH :
- chemical , adverse effects : Albendazole, Diethylcarbamazine, Filaricides.
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides.
- geographic : India.
- drug therapy : Elephantiasis, Filarial.
- methods : Communicable Disease Control.
- prevention & control : Elephantiasis, Filarial, Endemic Diseases.
- Adolescent, Adult, Animals, Child, Child, Preschool, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Patient Compliance, Program Evaluation, Treatment Outcome.
Abstract
The frequency and severity of adverse reactions are the main reasons for low compliance of mass drug administration (MDA) under the Programme to Eliminate Lymphatic Filariasis (PELF). This paper reports the frequency and types of adverse reactions during two MDAs during January 2002 and September 2004 in the State of Orissa, India. Of the people who consumed the drugs, 15.5% in the 2002 MDA and 16.5% in the 2004 MDA reported one or more adverse reactions. This rate is higher (49.7%) in a group of individuals who were monitored for 6 days from the day of consumption of drugs during the 2002 MDA. However, many of these reactions were mild. No significant difference was found in the frequency of adverse reactions between MDA with diethylcarbamazine (DEC) alone and with DEC and albendazole. Significant gender differences were found in the 2004 MDA but no such differences were found in the 2002 MDA; however, the frequency of adverse reactions increased with age. Of all the adverse reactions, systemic adverse reactions typically associated with microfilarial death were more frequent. The frequency of adverse reactions was higher in microfilaraemics compared with amicrofilaraemic controls. The present study warrants developing an active adverse reaction surveillance system to minimise the impact of adverse reactions on MDA compliance.
DOI: 10.1016/j.trstmh.2005.07.016
PubMed: 16288792
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B53
- to stream PubMed, to step Curation: 003B53
- to stream PubMed, to step Checkpoint: 003B53
- to stream Ncbi, to step Merge: 002026
- to stream Ncbi, to step Curation: 002026
- to stream Ncbi, to step Checkpoint: 002026
- to stream Main, to step Merge: 007C38
- to stream Main, to step Curation: 007A47
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.</title><author><name sortKey="Babu, B V" sort="Babu, B V" uniqKey="Babu B" first="B V" last="Babu">B V Babu</name><affiliation wicri:level="1"><nlm:affiliation>Clinical and Epidemiology Division, Regional Medical Research Centre, Indian Council of Medical Research, SE Rly Project Complex (Post), Bhubaneswar 751023, India. babuv@sify.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Clinical and Epidemiology Division, Regional Medical Research Centre, Indian Council of Medical Research, SE Rly Project Complex (Post), Bhubaneswar 751023</wicri:regionArea><wicri:noRegion>Bhubaneswar 751023</wicri:noRegion></affiliation></author><author><name sortKey="Rath, K" sort="Rath, K" uniqKey="Rath K" first="K" last="Rath">K. Rath</name></author><author><name sortKey="Kerketta, A S" sort="Kerketta, A S" uniqKey="Kerketta A" first="A S" last="Kerketta">A S Kerketta</name></author><author><name sortKey="Swain, B K" sort="Swain, B K" uniqKey="Swain B" first="B K" last="Swain">B K Swain</name></author><author><name sortKey="Mishra, S" sort="Mishra, S" uniqKey="Mishra S" first="S" last="Mishra">S. Mishra</name></author><author><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16288792</idno><idno type="pmid">16288792</idno><idno type="doi">10.1016/j.trstmh.2005.07.016</idno><idno type="wicri:Area/PubMed/Corpus">003B53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B53</idno><idno type="wicri:Area/PubMed/Curation">003B53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003B53</idno><idno type="wicri:Area/PubMed/Checkpoint">003B53</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003B53</idno><idno type="wicri:Area/Ncbi/Merge">002026</idno><idno type="wicri:Area/Ncbi/Curation">002026</idno><idno type="wicri:Area/Ncbi/Checkpoint">002026</idno><idno type="wicri:doubleKey">0035-9203:2006:Babu B:adverse:reactions:following</idno><idno type="wicri:Area/Main/Merge">007C38</idno><idno type="wicri:Area/Main/Curation">007A47</idno><idno type="wicri:Area/Main/Exploration">007A47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.</title><author><name sortKey="Babu, B V" sort="Babu, B V" uniqKey="Babu B" first="B V" last="Babu">B V Babu</name><affiliation wicri:level="1"><nlm:affiliation>Clinical and Epidemiology Division, Regional Medical Research Centre, Indian Council of Medical Research, SE Rly Project Complex (Post), Bhubaneswar 751023, India. babuv@sify.com</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Clinical and Epidemiology Division, Regional Medical Research Centre, Indian Council of Medical Research, SE Rly Project Complex (Post), Bhubaneswar 751023</wicri:regionArea><wicri:noRegion>Bhubaneswar 751023</wicri:noRegion></affiliation></author><author><name sortKey="Rath, K" sort="Rath, K" uniqKey="Rath K" first="K" last="Rath">K. Rath</name></author><author><name sortKey="Kerketta, A S" sort="Kerketta, A S" uniqKey="Kerketta A" first="A S" last="Kerketta">A S Kerketta</name></author><author><name sortKey="Swain, B K" sort="Swain, B K" uniqKey="Swain B" first="B K" last="Swain">B K Swain</name></author><author><name sortKey="Mishra, S" sort="Mishra, S" uniqKey="Mishra S" first="S" last="Mishra">S. Mishra</name></author><author><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name></author></analytic><series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title><idno type="ISSN">0035-9203</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Albendazole (adverse effects)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Communicable Disease Control (methods)</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Endemic Diseases (prevention & control)</term><term>Female</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>India</term><term>Male</term><term>Middle Aged</term><term>Patient Compliance</term><term>Program Evaluation</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (effets indésirables)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Contrôle des maladies contagieuses ()</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Incidence</term><term>Inde</term><term>Maladies endémiques ()</term><term>Mâle</term><term>Observance thérapeutique</term><term>Résultat thérapeutique</term><term>Études de suivi</term><term>Évaluation de programme</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Communicable Disease Control</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Endemic Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Patient Compliance</term><term>Program Evaluation</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Contrôle des maladies contagieuses</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Incidence</term><term>Inde</term><term>Maladies endémiques</term><term>Mâle</term><term>Observance thérapeutique</term><term>Résultat thérapeutique</term><term>Études de suivi</term><term>Évaluation de programme</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The frequency and severity of adverse reactions are the main reasons for low compliance of mass drug administration (MDA) under the Programme to Eliminate Lymphatic Filariasis (PELF). This paper reports the frequency and types of adverse reactions during two MDAs during January 2002 and September 2004 in the State of Orissa, India. Of the people who consumed the drugs, 15.5% in the 2002 MDA and 16.5% in the 2004 MDA reported one or more adverse reactions. This rate is higher (49.7%) in a group of individuals who were monitored for 6 days from the day of consumption of drugs during the 2002 MDA. However, many of these reactions were mild. No significant difference was found in the frequency of adverse reactions between MDA with diethylcarbamazine (DEC) alone and with DEC and albendazole. Significant gender differences were found in the 2004 MDA but no such differences were found in the 2002 MDA; however, the frequency of adverse reactions increased with age. Of all the adverse reactions, systemic adverse reactions typically associated with microfilarial death were more frequent. The frequency of adverse reactions was higher in microfilaraemics compared with amicrofilaraemic controls. The present study warrants developing an active adverse reaction surveillance system to minimise the impact of adverse reactions on MDA compliance.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><noCountry><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name><name sortKey="Kerketta, A S" sort="Kerketta, A S" uniqKey="Kerketta A" first="A S" last="Kerketta">A S Kerketta</name><name sortKey="Mishra, S" sort="Mishra, S" uniqKey="Mishra S" first="S" last="Mishra">S. Mishra</name><name sortKey="Rath, K" sort="Rath, K" uniqKey="Rath K" first="K" last="Rath">K. Rath</name><name sortKey="Swain, B K" sort="Swain, B K" uniqKey="Swain B" first="B K" last="Swain">B K Swain</name></noCountry><country name="Inde"><noRegion><name sortKey="Babu, B V" sort="Babu, B V" uniqKey="Babu B" first="B V" last="Babu">B V Babu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007A47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007A47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16288792
|texte= Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16288792" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |